ARCT News and Press, Arcturus Therapeutics Ltd. From 02/06/23

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare disease...

Summary Arcturus is revolutionizing biotechnology with its cutting-edge mRNA vaccines and delivery systems. They recently teamed up with CSL Seqirus, a leading player in the flu vaccine industry. The company still looks like a startup in an investment phase, but upfront payments fro...

Arcturus Therapeutics ( NASDAQ: ARCT ) said its clinical trial application (CTA) seeking to start a phase 1 study of inhaled mRNA medicine ARCT-032 to treat cystic fibrosis (CF), received approval in New Zealand. CF is an inherited disorder which damages the lungs, digestive syst...

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, “Arcturus Therapeutics”, Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities wi...

Summary ARK Invest’s 13F portfolio value decreased from $14.35B to $11.54B this quarter. They increased Tesla, Ginkgo Bioworks, and Coinbase Global stakes while decreasing NVIDIA, Fate Therapeutics, and TuSimple Holdings during the quarter. The top three positions are Exact S...

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare disease...

Dr. Markels, accomplished and experienced industry executive, most recently President of Global Vaccines at Merck, to provide strategic oversight to the Company’s vaccine franchise Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq:...

CSL Announces Closing of Global Collaboration and Licensing Agreement with Arcturus Therapeutics PR Newswire CSL to access late-stage next-generation mRNA platform technology, enabling development of vaccines for COVID-19, influenza, multi-pathogen pandemic preparedness and othe...

Summary Arcturus Therapeutics' tie-up with CSL secures financial stability for a number of years. Developing a diverse range of mRNA technology products for a variety of conditions. In a poor economic environment, biotechnology is an area not necessarily harmed by recessionary...

Baird downgraded the RNA therapeutics company Arcturus Therapeutics ( NASDAQ: ARCT ) on Thursday, citing an uncertain outlook for its recently announced partnership with Australia-based CSL Limited ( OTCPK:CSLLY ) ( OTC:CMHXF ) and seeing a delay in a key development pro...